CDC Article-US Medical Eligibility Criteria for Contraceptive Use, 2010

24 MMWR June 18, 2010
200. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect
of factor V Leiden and prothrombin 20210A on the risk of venous
thromboembolism—pooled analysis of 8 case-control studies including
2310 cases and 3204 controls. Study Group for Pooled-Analysis
in Venous Thromboembolism. Thromb Haemost 2001;86:809–16.
201. Gadelha T, Andre C, Juca AA, et al. Prothrombin 20210A and oral
contraceptive use as risk factors for cerebral venous thrombosis.
Cerebrovasc Dis 2005;19:49–52.
202. Legnani C, Palareti G, Guazzaloca G, et al. Venous thromboembolism
in young women: role of throbophilic mutations and oral contraceptive
use. Eur Heart J 2002;23:984–90.
203. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis
in carriers of a prothrombin-gene mutation and in users of oral
contraceptives [comment]. N Eng J Med 1998;338:1793–7.
204. Martinelli I, Taioli E, Bucciarelli P, et al. Interaction between the
G20210A mutation of the prothrombin gene and oral contraceptive
use in deep vein thrombosis. Arterioscler Thromb Vasc Biol
1999;19:700–3.
205. Martinelli I, Battaglioli T, Bucciarelli P, et al. Risk factors and recurrence
rate of primary deep vein thrombosis of the upper extremities.
Circulation 2004;110:566–70.
206. Martinelli I, Battaglia C, Burgo I, et al. Oral contraceptive use, thrombophilia
and their interaction in young women with ischemic stroke.
Haematologica 2006;91:844–7.
207. Middeldorp S, Meinardi JR, Koopman MM, et al. A prospective study
of asymptomatic carriers of the factor V Leiden mutation to determine
the incidence of venous thromboembolism [comment]. Ann Intern
Med 2001;135:322–7.
208. Pabinger I, Schneider B. Thrombotic risk of women with hereditary
antithrombin lll-, protein C- and protein S-deficiency taking oral contraceptive
medication. The GTH Study Group on Natural Inhibitors.
Thromb Haemost 1994;71:548–52.
209. Pezzini A, Grassi M, Iacoviello L, et al. Inherited thrombophilia and
stratification of ischaemic stroke risk among users of oral contraceptives.
J Neurol Neurosurg Psychiatry 2007;78:271–6.
210. Santamaria A, Mateo J, Oliver A, et al. Risk of thrombosis associated with
oral contraceptives of women from 97 families with inherited thrombophilia:
high risk of thrombosis in carriers of the G20210A mutation
of the prothrombin gene. Haematologica 2001;86:965–71.
211. Slooter AJ, Rosendaal FR, Tanis BC, et al. Prothrombotic conditions,
oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost
2005;3:1213–7.
212. Spannagl M, Heinemann LA, Schramm W. Are factor V Leiden carriers
who use oral contraceptives at extreme risk of venous thromboembolism?
Eur J Contracept Reprod Health Care 2000;5:105–12.
213. van Boven HH, Vandenbroucke JP, Briet E, et al. Gene-gene and geneenvironment
interactions determine risk of thrombosis in families with
inherited antithrombin deficiency. Blood 1999;94:2590–4.
214. van Vlijmen EF, Brouwer JL, Veeger NJ, et al. Oral contraceptives and
the absolute risk of venous thromboembolism in women with single
or multiple thrombophilic defects: results from a retrospective family
cohort study. Arch Intern Med 2007;167:282–9.
215. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous
thrombosis in oral-contraceptive users who are carriers of factor V
Leiden mutation [comment]. Lancet 1994;344:1453–7.
216. Vaya AM. Prothrombin G20210A mutation and oral contraceptive use
increase upper-extremity deep vein thrombotic risk. Thromb Haemost
2003;89:452–7.
217. The Criteria Committee of the New York Heart Association.
Nomenclature and criteria for diagnosis of diseases of the heart and
great vessels. 9th ed. Boston, MA: Little, Brown & Co; 1994.
218. Avila WS, Grinberg M, Melo NR, Aristodemo PJ, Pileggi F.
Contraceptive use in women with heart disease [in Portuguese]. Arq
Bras Cardiol 1996;66:205–11.
219. Bernatsky S, Ramsey-Goldman R, Gordon C, et al. Factors associated
with abnormal Pap results in systemic lupus erythematosus.
Rheumatology (Oxford) 2004;43:1386–9.
220. Bernatsky S, Clarke A, Ramsey-Goldman R, et al. Hormonal exposures
and breast cancer in a sample of women with systemic lupus erythematosus.
Rheumatology (Oxford) 2004;43:1178–81.
221. Chopra N, Koren S, Greer WL, et al. Factor V Leiden, prothrombin
gene mutation, and thrombosis risk in patients with antiphospholipid
antibodies. J Rheumatol 2002;29:1683–8.
222. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional
Framingham risk factors fail to fully account for accelerated atherosclerosis
in systemic lupus erythematosus. Arthritis Rheum
2001;44:2331–7.
223. Julkunen HA. Oral contraceptives in systemic lupus erythematosus:
side-effects and influence on the activity of SLE. Scand J Rheumatol
1991;20:427–33.
224. Julkunen HA, Kaaja R, Friman C. Contraceptive practice in women with
systemic lupus erythematosus. Br J Rheumatol 1993;32:227–30.
225. Jungers P, Dougados M, Pelissier C, et al. Influence of oral contraceptive
therapy on the activity of systemic lupus erythematosus. Arthritis
Rheum 1982;25:618–23.
226. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of
myocardial infarction and angina in women with systemic lupus erythematosus:
comparison with the Framingham Study. Am J Epidemiol
1997;145:408–15.
227. McAlindon T, Giannotta L, Taub N, et al. Environmental factors
predicting nephristis in systemic lupus erythematosus. Ann Rheum
Dis 1993;52:720–4.
228. McDonald J, Stewart J, Urowitz MB, et al. Peripheral vascular disease
in patients with systemic lupus erythematosus. Ann Rheum Dis
1992;51:56–60.
229. Mintz G, Gutierrez G, Deleze M, et al. Contraception with progestogens
in systemic lupus erythematosus. Contraception 1984;30:29–38.
230. Petri M. Musculoskeletal complications of systemic lupus erythematosus
in the Hopkins Lupus Cohort: an update. Arthritis Care Res
1995;8:137–45.
231. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives
in women with systemic lupus erythematosus. N Engl J Med
2005;353:2550–8.
232. Petri M. Lupus in Baltimore: evidence-based ‘clinical perarls’ from the
Hopkins Lupus Cohort. Lupus 2005;14:970–3.
233. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, et al. A trial of
contraceptive methods in women with systemic lupus erythematosus.
N Engl J Med 2005;353:2539–49.
234. Sarabi ZS, Chang E, Bobba R, et al. Incidence rates of arterial and
venous thrombosis after diagnosis of systemic lupus erythematosus.
Arthritis Rheum 2005;53:609–12.
235. Schaedel ZE, Dolan G, Powell MC. The use of the levonorgestrel-releasing
intrauterine system in the management of menorrhagia in women
with hemostatic disorders. Am J Obstet Gynecol 2005;193:1361–3.
236. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and
incidence of venous thrombosis in a cohort of patients with systemic
lupus erythematosus. J Rheumatol 2002;29:2531–6.